利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.02 秒)

    MULTISPECIFIC ANTIBODY PRODUCT THAT BINDS TO DIFFERENT ROR1 EPITOPES
    3.
    发明申请
    MULTISPECIFIC ANTIBODY PRODUCT THAT BINDS TO DIFFERENT ROR1 EPITOPES 审中-公开

    公开(公告)号：WO2019016381A1

    公开(公告)日：2019-01-24

    申请号：PCT/EP2018/069798

    申请日：2018-07-20

    申请人： NBE-THERAPEUTICS AG

    发明人： GRAWUNDER, Ulf ,  BEERLI, Roger ,  WALDMEIER, Lorenz

    IPC分类号： C07K16/28 ,  A61K47/68 ,  A61P35/00

    摘要： The present invention relates to a multi-specific product comprising a first entity comprising an antigen-binding domain that binds to the same RORl epitope as and/or competes for RORl binding with an antibody comprising a heavy chain variable region sequence shown in SEQ ID NO. 2 and a light chain variable region sequence shown in SEQ ID NO. 3; and a second entity comprising an antigen-binding domain that binds to a different target or RORl epitope than, and/or does not compete for binding with the antibody comprising a heavy chain variable region sequence shown in SEQ ID NO. 2 and a light chain variable region sequence shown in SEQ ID NO. 3.

    ANTI-MESOTHELIN ANTIBODIES
    4.
    发明申请
    ANTI-MESOTHELIN ANTIBODIES 审中-公开
    抗中性蛋白抗体

    公开(公告)号：WO2017072366A1

    公开(公告)日：2017-05-04

    申请号：PCT/EP2016/076255

    申请日：2016-10-31

    申请人： NBE-THERAPEUTICS AG

    发明人： HELLMANN, Ina ,  WALDMEIER, Lorenz ,  GRAWUNDER, Ulf ,  BEERLI, Roger

    IPC分类号： C07K16/30

    CPC分类号： C07K16/30 ,  A61K47/6803 ,  A61K47/6851 ,  A61K47/6889 ,  C07K2319/24 ,  C07K2319/30 ,  C07K2319/92

    摘要： The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Mesothelin (MN). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.

    摘要翻译： 本发明涉及靶向间皮素（MN）的人或人源化抗体或基于抗体的结合蛋白，修饰的抗体形式保持靶结合能力，抗体衍生物或片段保留靶结合能力， 。 其进一步涉及双特异性或多特异性抗体，免疫配体 - 药物偶联物，嵌合抗原受体和包含此类嵌合抗原受体的T细胞。

    ANTI-ROR1 ANTIBODIES
    7.
    发明申请
    ANTI-ROR1 ANTIBODIES 审中-公开
    抗ROR1抗体

    公开(公告)号：WO2017072361A1

    公开(公告)日：2017-05-04

    申请号：PCT/EP2016/076244

    申请日：2016-10-31

    申请人： NBE-THERAPEUTICS AG

    发明人： WALDMEIER, Lorenz ,  GRAWUNDER, Ulf ,  BEERLI, Roger

    IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K47/50

    CPC分类号： C07K16/2803 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6889 ,  C07K2317/24 ,  C07K2317/77 ,  C07K2317/92

    摘要： The present invention relates to a human or humanized antibody, or an antibody-based binding protein, modified antibody format retaining target binding capacity, antibody derivative or fragment retaining target binding capacity, which targets Receptor tyrosine kinase-like orphan receptor-1 (ROR1). It further relates to bi- or multispecific antibodies, to Immunoligand-Drug Conjugates, to Chimeric Antigen Receptors and to T-cells comprising such Chimeric Antigen Receptors.

    摘要翻译： 本发明涉及靶向受体酪氨酸激酶抑制剂的人或人源化抗体或基于抗体的结合蛋白，修饰的抗体形式保留靶结合能力，抗体衍生物或片段保留靶结合能力， 像孤儿受体-1（ROR1）。 其进一步涉及双特异性或多特异性抗体，免疫配体 - 药物偶联物，嵌合抗原受体和包含此类嵌合抗原受体的T细胞。

    SORTASE F AND ITS USE IN METHODS FOR CONJUGATION
    8.
    发明申请
    SORTASE F AND ITS USE IN METHODS FOR CONJUGATION 审中-公开

    公开(公告)号：WO2020089485A1

    公开(公告)日：2020-05-07

    申请号：PCT/EP2019/080116

    申请日：2019-11-04

    申请人： NBE-THERAPEUTICS AG

    发明人： GRAWUNDER, Ulf ,  BEERLI, Roger ,  GEBLEUX, Remy ,  PUORGER, Chasper ,  DI GIROLAMO, Salvatore ,  LIPPS, Georg

    IPC分类号： C12N9/52 ,  A61K38/16 ,  C07K16/28 ,  A61K47/68

    摘要： The present invention relates to a method for producing a conjugate of two substrates, the method comprising the steps of (a) providing two substrates, each substrate being independently selected from the one or more of the groups consisting of small molecules, and proteins, and (b) enzymatically conjugating the two substrates using a sortase F enzyme, or a catalytic domain thereof. One substrate comprises a sortase F recognition motif, while the other substrate comprises at least one motif selected from a Gly n motif, an Ala n motif, or a motif consisting of a mixture of Ala and Gly residues the motif totaling n residues, where n is an integer from ≥ 1 to ≤ 21. The reaction takes place in an aqueous reaction medium comprising a salt concentration of from about ≥ 0,01 to ≤ 3 M, thereby producing a conjugated product of the two substrates.

    LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS
    10.
    发明申请
    LIGAND ACTIVATED TRANSCRIPTIONAL REGULATOR PROTEINS 审中-公开
    配体激活的转录调节蛋白

    公开(公告)号：WO2001030843A1

    公开(公告)日：2001-05-03

    申请号：PCT/EP2000/010430

    申请日：2000-10-23

    申请人： NOVARTIS AG ,  THE SCRIPPS RESEARCH INSTITUTE

    发明人： BARBAS, Carlos, F. ,  KADAN, Michael ,  BEERLI, Roger

    IPC分类号： C07K14/47

    CPC分类号： C12N15/63 ,  A61K48/00 ,  C07K14/4702 ,  C07K14/70567 ,  C07K14/721 ,  C07K2319/00

    摘要： Fusion proteins for use as ligand-dependent transcriptional are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.

    摘要翻译： 提供用作配体依赖性转录的融合蛋白。 融合蛋白包括可操作地连接到配体结合结构域的核苷酸结合结构域。 它们还可以包括转录调节结构域。 核苷酸结合结构域是提供与3至18个核苷酸的靶向连续核苷酸序列结合的锌指肽。 融合蛋白用于基因治疗。 还提供了编码融合蛋白，表达载体和转染细胞的多核苷酸。